psoriasis

reshuffle pipeline target reorganize shift change
Biotech

Lilly shakes up pain pipeline as part of quarterly R&D clearout

Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion while adding a candidate from its recent SiteOne buyout.
Nick Paul Taylor Aug 7, 2025 8:28am
Vine jungle rainforest

Vyne prunes psoriasis trial, but keeps faith in BET inhibitor

Jul 2, 2025 10:33am
business targets illustration

Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win

May 21, 2025 6:25am
Vine jungle rainforest

Vyne’s psoriasis drug hit with FDA hold over testicular toxicity

Apr 25, 2025 9:25am
pivot change turnaround direction walk away

Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial

Apr 24, 2025 4:46am
scrabble tiles spelling out psoriasis

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu

Mar 10, 2025 7:30am